Opinion|Videos|October 4, 2024
Urgency to Treat in Lupus Nephritis: Goals of Therapy and Early Diagnosis Strategies
Panelists discuss the goals of therapy for lupus nephritis (LN), emphasizing the urgency of treatment to prevent renal flares and the consequences of untreated LN, as well as strategies for increasing early diagnosis and screening in patients with systemic lupus erythematosus.
Advertisement
Episodes in this series
- What are the goals of therapy for patients with lupus nephritis (LN)? What does urgency to treat mean in LN?
- What are the consequences of untreated LN or renal flares?
Objective: Examine strategies for early diagnosis/screening, updated treatment guidelines, and treatment and payer considerations to optimize lupus nephritis management and address patient access challenges.
- What strategies have you found effective in increasing the screening and early diagnosis of LN in patients with either diagnosed or suspected systemic lupus erythematosus (SLE)?
- Who are these patients who should be screened for LN?
How can payers support screening for LN in patients with SLE?
Advertisement
Related to this article
The Autus Size-Adjustable Valve, which can be expanded as children grow, may reduce the need for repeat open-heart surgeries for congenital defects.
A scoping review of 15 studies found psoriasis prevalence markedly lower across 13 indigenous populations worldwide.
A traditional Medicare out-of-pocket (OOP) cap could reduce beneficiaries’ costs but increase annual federal spending by $39 billion to $96 billion.
A systemic sclerosis inception cohort and 17-study meta-analysis found a nearly 5-fold increase in lung cancer risk.
Medicare Advantage plans have varied motivations, strategies, and aspirations for addressing health-related social needs among home health beneficiaries, highlighting a need to expand the scope of supplemental benefits.
2026 Nobel Prize in Medicine honors optogenetics pioneers who turn algae light-sensing protein into neural switches, transforming brain mapping and enabling vision-restoration trials.
Medicare's Transforming Episode Accountability Model is projected to save $46.6 million by 2030, with safety-net hospitals potentially receiving the highest reconciliation payments.
A comparison of 2013 and 2022 data shows that cancer costs are not uniformly rising. Costs decreased for metastatic colorectal cancer but increased for both metastatic non–small cell lung cancer and multiple myeloma.
Advertisement
Advertisement
Trending on AJMC
1
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
2
Closing Reflections on the Future of Vitiligo Care
3
VBC Risk Is Outpacing Provider Readiness, CMS Must Act
4
FDA Approves Pirtobrutinib for Untreated CLL/SLL Without 17p Deletion
5